Dr. Scott T. Tagawa, MD

Dr. Tagawa practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Tagawa's NPI, 1245258045, was assigned on July 18, 2006. Dr. Tagawa graduated from Keck School of Medicine of USC in 1998. Dr. Tagawa holds California license 70818.

Dr. Tagawa's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Tagawa's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Tagawa to 2 more clinical labs, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tagawa practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tagawa's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tagawa is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Tagawa's licenses on file in 2 states: California and New York.

Dmand AI lists chronic leukemia, lymphoma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Tagawa treats.

CMS data shows 895 Medicare services from Dr. Tagawa across 3 procedure codes in 2024, all of them office visits, for 231 Medicare patients. Medicare paid $111,310 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 231 Medicare patients who saw Dr. Tagawa in 2024. The largest group is 75 to 84, with 102 patients. 75% of them have cancer, and 75% have high blood pressure. 10% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tagawa's median patient age at 76, with 3% women.

In 2024, Dr. Tagawa wrote 139 Medicare Part D claims for 41 patients. 92% of them were for generic drugs. CMS names the drug for 56 of them, across 3 drugs with 11 or more claims each, at $363 in total drug cost. In 2023, CMS named 62 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Tagawa for performance year 2024, reported through an alternative payment model (APM). Dr. Tagawa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tagawa as offering telehealth.

Dmand AI links 182 papers to Dr. Tagawa, published from 2010 to 2025. 2021 was the busiest year, with 22. The most frequent topics are Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant and Neoplasm Metastasis. Dr. Tagawa has published most often in J Clin Oncol. Dr. Tagawa's most frequent co-authors are David M. Nanus, MD, Himisha Beltran, MD and Joseph R. Osborne, MD.

Dmand AI links Dr. Tagawa to 21 clinical trials, 5 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Urethral Neoplasms. Weill Medical College of Cornell University sponsors the most, 10. Open Payments lists research payments to Dr. Tagawa that name 6 trials.

CMS Open Payments shows 488 general payments to Dr. Tagawa from 35 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. Sanofi and Genzyme US Companies paid the most, $56,399. It also lists 33 research payments totaling $27,139 from 2016 to 2025, naming 6 clinical trials.

Dmand AI lists 5 awards for Dr. Tagawa, most recently America's Top Doctors in 2014.

Dr. Tagawa graduated from Keck School of Medicine of USC in 1998. Dr. Tagawa is a member of ACP, ASCO, ASH and AUA.

Dr. Tagawa is in network with 16 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.